
Proud of this study and the data it provides for peds hemophilia A patients as we strive for optimal health ❤️💉🩸 Efanesoctocog Alfa Prophylaxis for Children with Severe Hemophilia A | New England Journal of Medicine nejm.org/doi/full/10.1056/NE…

pediatric/adult hematologist with hemophilia focus, passionate to improve care for women/girls with bleeding disorders, clinical researcher, proud cheesehead

Proud of this study and the data it provides for peds hemophilia A patients as we strive for optimal health ❤️💉🩸 Efanesoctocog Alfa Prophylaxis for Children with Severe Hemophilia A | New England Journal of Medicine nejm.org/doi/full/10.1056/NE…

Joshua Muia kicking off #HTRS2025 Research Colloquium sharing how @HTRStoday help build careers in hemostasis and thrombosis.

Lynn Malec presents the latest from the XTEND-ed Phase 3 study! The second interim analysis reveals two-year clinical outcomes of once-weekly efanesoctocog alfa #prophylaxis in children with severe #haemophilia A. How does it impact bleed control and quality of life? #EAHAD2025

Me watching the votes roll in while my 7 y.o. exercises her Montessorian muscles tracking the electoral map

Montgomery Educational Symposium on Hemostasis (MESH) was a huge success thanks to the incredibly bright minds and warm hearts that gathered to honor ‘Montgomery, Milwaukee’s’ amazing career @VersitiResearch

Such a great experience to partner with @pjlynch on this episode 🎙️ ALWAYS more to learn! Staying curious drives improvements for patients 👏🏼
If experts like Dr. Lynn Malec are still learning about #jointhealth and #hemophilia, think about how much there is still to learn, and account for, for most patients.

If experts like Dr. Lynn Malec are still learning about #jointhealth and #hemophilia, think about how much there is still to learn, and account for, for most patients.
New insights from the EXTEND study reveal improved hemophilia joint health scores! Learn more in our latest episode of Global Hemophilia Report. bit.ly/ghr_podlink Featured Advertiser: @SanofiUS

Expanded space, expanded collaborations, expanded discoveries
Versiti begins $79M expansion in Wauwatosa, but funding still needed - Milwaukee Business Journal bizjournals.com/milwaukee/ne… via @MKEBizJournal

It is time for one of the most famous slides in #hemophilia to be updated. Paper in @JTHjournal describes prospectively collected bleeding rate data in 825 children with mild hemophilia. tinyurl.com/yt4vvnes

Check out publication by VBRI Senior investigator Qizhen Shi @QizhenShi and collaborators Anti-mCD20 in combination with α-mCXCL13 monoclonal antibody inhibits anti-FVIII antibody development in hemophilia… pubmed.ncbi.nlm.nih.gov/3906…

Interested in a Hematology position at Versiti? My biased opinion is our team is phenomenal 😉 Associate Medical Director/Medical Director, Versiti Medical Sciences Institute/CCBD- Adult and/or Med/Peds Hematologist (#Milwaukee, Wisconsin) #job social.icims.com/viewjob/pt1…

So well deserved! @JuliPerezBot you are amazing!
Congrats to @JuliPerezBot, who was named an Exceptional Woman in Medicine by @MKElifestyle. Learn more about her work: versiti.org/versiti-blood-re… #VersitiResearch #VersitiScience #MKElifestyle

So great to participate in this collaboration! Always inspiring to work/present along side you 👊🏼💜
This tweet is unavailable

A pediatric legend and the heart and soul of @residentsofchp . Dena taught us every day by example and with sage advice that led to a generation of Pittsburgh Pediatricians. She will be missed.
We would like to remember and honor the memory of Dr. Dena Hofkosh, Emeritus Professor of Pediatrics, who passed Tuesday morning. She will be greatly missed by all. Please read Dr. Dermody's message here: pediatrics.pitt.edu/news/mes… @ChildrensPgh @UPMCPhysicianEd @PittHealthSci

Exciting work from Zheng lab!
Hope this review article give you the aha moments that it gave us when we wrote it. @DrWenDai1

Gene therapy for hemophilia A has arrived in the US. U.S. Food and Drug Administration Approves BioMarin's ROCTAVIAN™ (valoctocogene roxaparvovec-rvox), the First and Only Gene Therapy for Adults with Severe Hemophilia A prnewswire.com/news-releases…